A
AMLX
Amylyx Pharmaceuticals, Inc. Common Stock
$27.03
Current Price
1W
1M
3M
6M
1Y
All
AI analysis
Read what the AI thinks of Amylyx Pharmaceuticals, Inc. Common Stock in the app.
Analyses are generated by AI from public data and are not investment advice.
Get the app
Key figures
Dividend per share
—
Yield
—
EPS
-$1.43
P/E
—
Data as of Oct 8
Why it matters for the long term
Over 10-20 years, what drives a share up is the growth of its profits (EPS) + reinvested dividends. The P/E tells you whether you are paying a lot or a little for that growth. In short: rising EPS + reasonable P/E + growing dividend = good long-term candidate.
Upcoming events
Quarterly earnings
Expected EPS: -$0.40
Nov 5
Posts
No posts about AMLX yet.
About Amylyx Pharmaceuticals, Inc. Common Stock
Amylyx Pharmaceuticals is a US drug developer. It does not yet have a steady stream of product sales, so it funds its work from cash raised from investors. Its main project is a hormone-based drug called avexitide, aimed at conditions where blood sugar drops too low, such as after weight-loss surgery. The company makes money only if a drug wins regulatory approval and sells.